TERM ID="NYU_TERM_1" STRING="3A4" FREQUENCY=1 START=1524 END=1527 LEMMA="3A4" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_2" STRING="CYP" FREQUENCY=1 START=1519 END=1522 LEMMA="CYTOCHROME P450" LEMMA_FREQUENCY=3
TERM ID="NYU_TERM_3" STRING="IV" FREQUENCY=1 START=507 END=509 LEMMA="IV" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_4" STRING="Intravenous temsirolimus" FREQUENCY=1 START=0 END=24 LEMMA="INTRAVENOUS TEMSIROLIMUS" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_5" STRING="PK" FREQUENCY=1 START=1698 END=1700 LEMMA="PHARMACOKINETIC" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_6" STRING="PK profile" FREQUENCY=1 START=1842 END=1852 LEMMA="PK PROFILE" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_7" STRING="Temsirolimus" FREQUENCY=3 START=93 END=105 LEMMA="TEMSIROLIMUS" LEMMA_FREQUENCY=8
TERM ID="NYU_TERM_8" STRING="Temsirolimus" FREQUENCY=3 START=564 END=576 LEMMA="TEMSIROLIMUS" LEMMA_FREQUENCY=8
TERM ID="NYU_TERM_9" STRING="Temsirolimus" FREQUENCY=3 START=1155 END=1167 LEMMA="TEMSIROLIMUS" LEMMA_FREQUENCY=8
TERM ID="NYU_TERM_10" STRING="addition" FREQUENCY=1 START=1306 END=1314 LEMMA="ADDITION" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_11" STRING="administration" FREQUENCY=2 START=511 END=525 LEMMA="ADMINISTRATION" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_12" STRING="administration" FREQUENCY=2 START=1230 END=1244 LEMMA="ADMINISTRATION" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_13" STRING="anticancer agents" FREQUENCY=1 START=2008 END=2025 LEMMA="ANTICANCER AGENT" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_14" STRING="being explored" FREQUENCY=1 START=1062 END=1076 LEMMA="BEING EXPLORED" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_15" STRING="bioavailability" FREQUENCY=1 START=455 END=470 LEMMA="BIOAVAILABILITY" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_16" STRING="cancer patients" FREQUENCY=2 START=28 END=43 LEMMA="CANCER PATIENT" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_17" STRING="cancer patients" FREQUENCY=2 START=1897 END=1912 LEMMA="CANCER PATIENT" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_18" STRING="clinical pharmacology" FREQUENCY=1 START=45 END=66 LEMMA="CLINICAL PHARMACOLOGY" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_19" STRING="considerations" FREQUENCY=1 START=78 END=92 LEMMA="CONSIDERATION" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_20" STRING="considerations Temsirolimus" FREQUENCY=1 START=78 END=105 LEMMA="TEMSIROLIMUS CONSIDERATION" LEMMA_FREQUENCY=1 HEAD_TERM="Temsirolimus" HEAD_LEMMA="TEMSIROLIMUS"
TERM ID="NYU_TERM_21" STRING="cytochrome P450" FREQUENCY=2 START=1502 END=1517 LEMMA="CYTOCHROME P450" LEMMA_FREQUENCY=3
TERM ID="NYU_TERM_22" STRING="cytochrome P450" FREQUENCY=2 START=1502 END=1517 LEMMA="CYTOCHROME P450" LEMMA_FREQUENCY=3
TERM ID="NYU_TERM_23" STRING="distribution" FREQUENCY=1 START=1194 END=1206 LEMMA="DISTRIBUTION" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_24" STRING="dosage results" FREQUENCY=1 START=879 END=893 LEMMA="DOSAGE RESULT" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_25" STRING="drug interaction" FREQUENCY=1 START=1702 END=1718 LEMMA="DRUG INTERACTION" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_26" STRING="drug interaction studies" FREQUENCY=1 START=1529 END=1553 LEMMA="DRUG INTERACTION STUDY" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_27" STRING="equipotent metabolite" FREQUENCY=1 START=1404 END=1425 LEMMA="EQUIPOTENT METABOLITE" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_28" STRING="equipotent metabolite of temsirolimus" FREQUENCY=1 START=1404 END=1441 LEMMA="TEMSIROLIMUS EQUIPOTENT METABOLITE" LEMMA_FREQUENCY=1 HEAD_TERM="equipotent metabolite" HEAD_LEMMA="EQUIPOTENT METABOLITE"
TERM ID="NYU_TERM_29" STRING="extensive distribution" FREQUENCY=1 START=1255 END=1277 LEMMA="EXTENSIVE DISTRIBUTION" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_30" STRING="formulation" FREQUENCY=1 START=710 END=721 LEMMA="FORMULATION" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_31" STRING="hematologic malignancies" FREQUENCY=1 START=1097 END=1121 LEMMA="HEMATOLOGIC MALIGNANCY" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_32" STRING="immunosuppressive activity" FREQUENCY=1 START=947 END=973 LEMMA="IMMUNOSUPPRESSIVE ACTIVITY" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_33" STRING="including mantle cell lymphoma" FREQUENCY=1 START=1123 END=1153 LEMMA="INCLUDING MANTLE CELL LYMPHOMA" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_34" STRING="intravenous" FREQUENCY=1 START=494 END=505 LEMMA="INTRAVENOUS" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_35" STRING="intrinsic mTOR inhibitory activity" FREQUENCY=1 START=633 END=667 LEMMA="INTRINSIC MTOR INHIBITORY ACTIVITY" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_36" STRING="mTOR" FREQUENCY=1 START=169 END=173 LEMMA="MAMMALIAN TARGET OF RAPAMYCIN" LEMMA_FREQUENCY=3
TERM ID="NYU_TERM_37" STRING="mTOR inhibitor" FREQUENCY=1 START=261 END=275 LEMMA="MTOR INHIBITOR" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_38" STRING="mammalian target" FREQUENCY=1 START=138 END=154 LEMMA="MAMMALIAN TARGET" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_39" STRING="mammalian target of rapamycin" FREQUENCY=2 START=138 END=167 LEMMA="MAMMALIAN TARGET OF RAPAMYCIN" LEMMA_FREQUENCY=3
TERM ID="NYU_TERM_40" STRING="mammalian target of rapamycin" FREQUENCY=2 START=138 END=167 LEMMA="MAMMALIAN TARGET OF RAPAMYCIN" LEMMA_FREQUENCY=3
TERM ID="NYU_TERM_41" STRING="mg" FREQUENCY=1 START=870 END=872 LEMMA="MG" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_42" STRING="monotherapy" FREQUENCY=1 START=1967 END=1978 LEMMA="MONOTHERAPY" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_43" STRING="optimal clinical benefit" FREQUENCY=1 START=538 END=562 LEMMA="OPTIMAL CLINICAL BENEFIT" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_44" STRING="oral rapamycin" FREQUENCY=1 START=277 END=291 LEMMA="ORAL RAPAMYCIN" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_45" STRING="peak temsirolimus concentrations" FREQUENCY=1 START=902 END=934 LEMMA="PEAK TEMSIROLIMUS CONCENTRATION" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_46" STRING="peripheral tissues" FREQUENCY=1 START=1283 END=1301 LEMMA="PERIPHERAL TISSUE" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_47" STRING="pharmacokinetic" FREQUENCY=1 START=1681 END=1696 LEMMA="PHARMACOKINETIC" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_48" STRING="rapamycin" FREQUENCY=3 START=158 END=167 LEMMA="RAPAMYCIN" LEMMA_FREQUENCY=3
TERM ID="NYU_TERM_49" STRING="rapamycin" FREQUENCY=3 START=599 END=608 LEMMA="RAPAMYCIN" LEMMA_FREQUENCY=3
TERM ID="NYU_TERM_50" STRING="rapamycin" FREQUENCY=3 START=1382 END=1391 LEMMA="RAPAMYCIN" LEMMA_FREQUENCY=3
TERM ID="NYU_TERM_51" STRING="renal cell carcinoma" FREQUENCY=1 START=752 END=772 LEMMA="RENAL CELL CARCINOMA" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_52" STRING="sirolimus" FREQUENCY=2 START=1371 END=1380 LEMMA="SIROLIMUS" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_53" STRING="sirolimus" FREQUENCY=2 START=1468 END=1477 LEMMA="SIROLIMUS" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_54" STRING="sirolimus metabolite" FREQUENCY=1 START=1635 END=1655 LEMMA="SIROLIMUS METABOLITE" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_55" STRING="solubility" FREQUENCY=1 START=692 END=702 LEMMA="SOLUBILITY" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_56" STRING="targeted therapy" FREQUENCY=1 START=198 END=214 LEMMA="TARGETED THERAPY" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_57" STRING="temsirolimus" FREQUENCY=5 START=774 END=786 LEMMA="TEMSIROLIMUS" LEMMA_FREQUENCY=8
TERM ID="NYU_TERM_58" STRING="temsirolimus" FREQUENCY=5 START=983 END=995 LEMMA="TEMSIROLIMUS" LEMMA_FREQUENCY=8
TERM ID="NYU_TERM_59" STRING="temsirolimus" FREQUENCY=5 START=1429 END=1441 LEMMA="TEMSIROLIMUS" LEMMA_FREQUENCY=8
TERM ID="NYU_TERM_60" STRING="temsirolimus" FREQUENCY=5 START=1451 END=1463 LEMMA="TEMSIROLIMUS" LEMMA_FREQUENCY=8
TERM ID="NYU_TERM_61" STRING="temsirolimus" FREQUENCY=5 START=1859 END=1871 LEMMA="TEMSIROLIMUS" LEMMA_FREQUENCY=8
TERM ID="NYU_TERM_62" STRING="temsirolimus dose adjustments" FREQUENCY=1 START=1731 END=1760 LEMMA="TEMSIROLIMUS DOSE ADJUSTMENT" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_63" STRING="undergoes extensive first-pass metabolism" FREQUENCY=1 START=315 END=356 LEMMA="UNDERGOES EXTENSIVE FIRST-PASS METABOLISM" LEMMA_FREQUENCY=1
